China’s Bold Takeda Choice: LIVTENCITY’s Unique Edge
Takeda has announced the approval of LIVTENCITY® (maribavir) by the National Medical Products Administration (NMPA) of China for treating...
AI in Action: Medidata Focuses on Data Entry, Diverse Trials
Dive into the forefront of clinical trial innovation with our interview featuring Anthony Costello from Medidata. We discuss groundbreaking...
Breaking New Ground: AstraZeneca, Roche, Acadia in GCP & AI
The 2nd GCP Inspection Readiness Conference, convened by Momentum Events, attracted a significant gathering of clinical experts in the...
uMotif Shaping New Patient-Centric Design in Clinical Trials
In today’s dialogue, we are privileged to converse with Bruce Hellman from uMotif, a company at the forefront of...
AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested
Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their...
Gilead’s $848M Bet on Compugen’s Revolutionary Therapy
Gilead Sciences, Inc. has entered into an agreement with Israeli company Compugen Ltd., a clinical-stage cancer immunotherapy firm, to...
Zurzuvae: New Hope Pill for Moms with Post-Partum Depression
Sage Therapeutics, Inc. and Biogen Inc. have announced the availability of ZURZUVAE™ (zuranolone) by prescription in the United States...
FDA Nods to Padcev-Keytruda for Bladder Cancer
Pfizer Inc. and Astellas Pharma Inc. have announced the FDA’s approval of PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC])...
BMS’s RELATIVITY-123 Trial Fail: A Devastating End
Bristol Myers Squibb announced the discontinuation of the Phase 3 RELATIVITY-123 trial, which was evaluating the fixed-dose combination of...
Pfizer Seals Deal: Seagen Now Acquired for $229/Share
Pfizer Inc. has announced the completion of its acquisition of Seagen Inc., marking a significant expansion in its commitment...